Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Strober

Showing results (21-30 of 129) with videos related to

Pageof 13
Sort By:
Journal of Drugs in Dermatology : JDD|November 9, 2012
PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agentsKim A Papp, Bruce Strober, Matthias Augustin, et al.
Dermatology and Therapy|July 18, 2021
A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment ParadigmBruce Strober, David Pariser, Ann Deren-Lewis, et al.
The Journal of Dermatological Treatment|July 15, 2022
Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal respondersBruce Strober, April Armstrong, Simone Rubant, et al.
Dermatology and Therapy|October 25, 2024
Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque PsoriasisApril W Armstrong, Ahmed M Soliman, Paolo Gisondi, et al.
Journal of Psoriasis and Psoriatic Arthritis|June 2, 2025
All-Cause Mortality is Higher in Generalized Pustular Psoriasis (GPP) than Plaque Psoriasis and the General Population: A US-Based Claims AnalysisAlice B Gottlieb, Hannah Crooke Kwiatkowski, Juan Semeco, et al.
Journal of the American Academy of Dermatology|September 1, 2025
Real-world treatment patterns in patients with generalized pustular psoriasis (GPP)Bruce Strober, Hannah Kwiatkowski, Layla Lavasani, et al.
American Journal of Clinical Dermatology|June 27, 2024
Association Between Biologic Exposure and the Risk of Depression in Patients with Psoriasis: A Retrospective Analysis of Large US Administrative Claims DataBruce Strober, Ahmed M Soliman, Bang Truong, et al.
Dermatology and Therapy|May 13, 2022
Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World SettingBruce Strober, Dhaval Patil, Robert R McLean, et al.
Journal of Psoriasis and Psoriatic Arthritis|November 25, 2024
Criteria for Identifying Candidates for Systemic Psoriasis Treatment in the Real World: Application of the International Psoriasis Council Guidelines in Patients in North AmericaBruce Strober, Yichen Zhong, Adam Sima, et al.
Journal of the American Academy of Dermatology|October 21, 2017
Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis RegistryBruce Strober, Chitra Karki, Marc Mason, et al.
Pageof 13

Showing results (21-30 of 129) with videos related to

Sort By:
Pageof 13
Journal of Drugs in Dermatology : JDD|November 9, 2012
PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agentsKim A Papp, Bruce Strober, Matthias Augustin, et al.
Dermatology and Therapy|July 18, 2021
A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment ParadigmBruce Strober, David Pariser, Ann Deren-Lewis, et al.
The Journal of Dermatological Treatment|July 15, 2022
Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal respondersBruce Strober, April Armstrong, Simone Rubant, et al.
Dermatology and Therapy|October 25, 2024
Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque PsoriasisApril W Armstrong, Ahmed M Soliman, Paolo Gisondi, et al.
Journal of Psoriasis and Psoriatic Arthritis|June 2, 2025
All-Cause Mortality is Higher in Generalized Pustular Psoriasis (GPP) than Plaque Psoriasis and the General Population: A US-Based Claims AnalysisAlice B Gottlieb, Hannah Crooke Kwiatkowski, Juan Semeco, et al.
Journal of the American Academy of Dermatology|September 1, 2025
Real-world treatment patterns in patients with generalized pustular psoriasis (GPP)Bruce Strober, Hannah Kwiatkowski, Layla Lavasani, et al.
American Journal of Clinical Dermatology|June 27, 2024
Association Between Biologic Exposure and the Risk of Depression in Patients with Psoriasis: A Retrospective Analysis of Large US Administrative Claims DataBruce Strober, Ahmed M Soliman, Bang Truong, et al.
Dermatology and Therapy|May 13, 2022
Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World SettingBruce Strober, Dhaval Patil, Robert R McLean, et al.
Journal of Psoriasis and Psoriatic Arthritis|November 25, 2024
Criteria for Identifying Candidates for Systemic Psoriasis Treatment in the Real World: Application of the International Psoriasis Council Guidelines in Patients in North AmericaBruce Strober, Yichen Zhong, Adam Sima, et al.
Journal of the American Academy of Dermatology|October 21, 2017
Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis RegistryBruce Strober, Chitra Karki, Marc Mason, et al.
Pageof 13